Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 4/20 | 0.48 |
| ▸ | FLT1 | P17948 | 2/20 | 0.48 |
| ▸ | FLT4 | P35916 | 2/20 | 0.48 |
| ▸ | RET | P07949 | 2/20 | 0.46 |
| ▸ | MAP3K14 | Q99558 | 4/20 | 0.46 |
| ▸ | PKD2 | Q13563 | 1/20 | 0.46 |
| ▸ | IGF1R | P08069 | 3/20 | 0.43 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | SMG1 | Q96Q15 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4244620 | 0.89 | PTK2 (0.52) | KDRFLT1RETIGF1RALK | |
| SCHEMBL13911389 | 0.84 | ROCK1 (0.44) | KDRFLT1FLT4RETMAP3K14 | |
| SCHEMBL4245472 | 0.82 | AIMP2 (0.42) | KDRFLT1FLT4RETMAP3K14 | |
| SCHEMBL4660744 | 0.82 | CDK2 (0.48) | KDRIGF1RALKCDK4CDK2 | |
| SCHEMBL4245377 | 0.81 | RET (0.39) | KDRFLT4RETMAP3K14SYK | |
| SCHEMBL27760699 | 0.80 | ROCK1 (0.38) | FLT4RETMAP3K14ROCK1MTOR | |
| SCHEMBL4247112 | 0.80 | IKBKB (0.43) | KDRRETSYKCDK4CDK2 | |
| SCHEMBL4252261 | 0.78 | CCNT1 (0.50) | IGF1RCDK2GSK3BROCK1MTOR | |
| SCHEMBL4248238 | 0.78 | EGFR (0.56) | SRCEGFR | |
| SCHEMBL13911365 | 0.76 | AXL (0.47) | MTORSMG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069360-A1 | Organic Compounds | CARAVATTI, GIORGIO (CH) | 2009-03-12 | — | — | US | disclosed |
| EP-2001864-A1 | HETEROCYCLIC ORGANIC COMPOUNDS FOR THE TREATMENT OF IN PARTICULAR MELANOMA | Novartis Pharma AG (CH) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007109045-A1 | HETEROCYCLIC ORGANIC COMPOUNDS FOR THE TREATMENT OF IN PARTICULAR MELANOMA | NOVARTIS AG (CH) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069360-A1 | Organic Compounds | BRAF, MAP3K1, RAF1 | KDR 37/4885FLT1 34/4885FLT4 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.